NEW AND OLD STANDBY DRUG THERAPIES

摘要

There are literally hundreds of ophthalmic formulations on the market, some relegated to veterinary species but the majority labeled for human use. Despite this seemingly endless variety of available pharmaceuticals, veterinary ophthalmologists oftenfind themselves–and their patients – at the mercy of therapeutic trends in human medicine. As an example, availability of oral carbonic anhydrase inhibitors has suffered as topical agents become the standard in human glaucoma management. On the other hand, canine patients have benefited substantially from development of topical anti-glaucoma agents such as latanoprost. Unfortunately the cost of these new products is also substantial. Not even ophthalmologists find it practical or prudent to include all of these medications in their office inventory.